Intercontinental

Disease site: Urological

Treatment Modality: Hormone Therapy

Status: In active follow-up

The aim is to evaluate the use of intermittent androgen suppression (IAS) for overall survival, the potential for an improved quality of life during the non-treatment interval and decreased cost of therapy compared to continuous androgen ablation.

The trial is coordinated by the National Cancer Institute of Canada with ICR-CTSU responsible for UK centres. In the UK the trial is supported by the NCRI Prostate Clinical Studies Group.

The trial has recruited 1386 patients internationally.

UK Chief Investigator: Prof D. P. Dearnaley, Royal Marsden Hospital, Sutton.

Sponsor: Institute of Cancer Research

Source of UK funding: Cancer Research UK.

ISRCTN: 22761545.